""Wednesday is The Day! The Dragonfly - Doji is NEVER wrong! Mark my words!""
I will say that it is wrong.
H, ha. A pharmacist and biotech investment consultant writing about a company he is invested in deeply. Ha, ha. Chris is an uber long and his "analysis" isn't worth the paper it is written on. Since it isn't actually written on paper, you can see how little that is worth. I especially liked the part where he wrote about a partnership being a certainly that will be worth a kings ransom. Ha, ha. Bavi has never been shown to significantly improve survival in a controlled trial, the most advanced trial, the phase II NSCLC trial was corrupted and contains 50% censored patients in the 3mg/kg arm,
I love it when someone like alan calls others imbeciles, then displays their own ignorance. You don't even know how to properly use" their ". Here is some more news for you. The tea party imbeciles are responsible as they submit a budget they know will be rejected. As far as Obamacare, the Republicans refused to be involved in any aspect of crafting the law, or in trying to improve it after it was passed, signed into law then upheld as constitutional by the Supreme Court. The fact that you call Obamacare dung demonstrates you lack of knowledge of that law, and your familiarity with dung.
At this point, the Enchant-1 trial is so early that it can't possibly drive the stock price higher. We will have to win until the December update comes. The HSP90 conjugates are to new to have any meaningful impact on the stock price. Likely more than a year or two away from any impact.
ahhahah the moron is back. It is flattering that you follow me around, I guess you made a lot of money following me on my two biggest holdings, ONXX and IMGN, the latter I bought most of my shares after it cratered on the FDA rejection a few years ago. I recently bought more IMGN at $13.52.
Welcome Ivan. SNTA's biggest problems were that management was initially too focused on Ganetespib as a monotherapy. AS you state, Ganetespib has an excellent safety profile, and that makes it very amenable to combination therapies, which thankfully management has now fully embraced. A second issue is that management was setting itself up for disappointments by making comments about impressive efficacy signals well before trials were completed, or even significantly through the trial. It looks like they have finally learned their lesson, to keep expectations low and their heads down until the data starts rolling so the data can speak for itself. Lastly, management is moving forward in breast cancer where an HSP90i should be very efficacious as ERBs are major clients of HSP90.
Nothing unexpected here. Of course SNTA has to raise some cash, and they have to do it before the Enchant-1 breast cancer data is released. Management was remiss in not doing it before the update of Galaxy-1. The people who were talking about how the Galaxy-1 update was great if they just omitted the two "outlier" Eastern European enrollment sites should have realized that things weren't so clean and easy when SNTA increased the size of Galaxy-2. After we get an idea of the size and price of the new share offering, and after the stock reacts, I will consider buying back some of the shares I sold at $5.13. If the Enchant-1 data looks good and stock rises significantly, then I will sell some again.
The post deserves a thumbs down because it is non-sense posted by a delusional pumper. PPHM fares poorly compared to the NASDAQ in almost any time frame you can use. The fact that a pumper finds one very short time frame where the opposite is true is meaningless and irrelevant.
jonesdexter, Don't be so stupid. The looming government shutdown and the prospects the imbecile tea party will push the country to default over the debt ceiling is what the problems are now.
Respitamycin had liver and ocular toxicity issues because of its hydrophobicity. INFI converted it to a salt, respitamycin:HCl in the hopes the ionic form would not have toxicity issues. The problem is that 50% of the salt converts in the blood, due to blood pH) back to the free base. They had to lower the dose to make sure it wouldn't reach toxic levels and there was no guarantee the salt would be as efficacious.
The idea that if one HSPi inhibitor fails means all will fail is absurd. There are many tyrosine kinase inhibitors on the market and they have different efficacies in different cancer types. An excellent example is the comparison of Sutent and Nexavar. The failure of Respitamycin is INFI specific, and as such I think this is a buying opportunity regarding SNTA.
hailstorm, I see you don't know anything about either Biotech companies or drug development. It is almost unheard of for a company to get a drug to market in 10 years.
JFK, I didn't mean to offend you by the erratic comment. It was just that you seem to swing back and forth a bit on how you feel about SNTA based on thing I don't think are important. monotherapy isn't as important as maximizing efficacy. Avastin doesn't do well as monotherapy but does well as combination therapy. Any analyst who thinks adding a combination arm to a phase II exploratory study is somehow bad news or is skeptical is pretty clueless. The point of a phase II trial is to define the population, and treatment regimen that will be used in the phase III trial. A good company will take time to make sure that the phase II trial can be used for that purpose. The monotherapy Ganetespib data was pretty good, but based on data which was generated after Enchant started, it became clear that combination with other drugs, and the lung cancer trial says docetaxel does so. As the drug paclitaxel is essentially docetaxel and is used in breast cancer, it is a smart and prudent move to add that combo arm to Enchant, even if it delays the phase III start.
Billydbaseball and wilderguider, you are both on target with your posts. The NSCLC data released for the current ESMO is basically the same presentation as was shown at ASCO earlier this year. The final data release is what we need to see, and that won't be until later this year. The inhibition of new metastatic lesions is intriguing and may provide the solid rationale for improved OS, but again that was presented at ASCO earlier this year. Wilder, your comment on OS is exactly right.
As far as JFK, he appears to be some kind of boiler room pumper so I wouldn't worry too much about what he or she says. It helps to put people like that on ignore as I did. I am also anxious to see updated results from Enchant-1, especially the combination arm of Ganetespib + paclitaxel as that is how Ganetepsib will almost certainly be used in breast cancer rather than as a monotherapy.
There was nothing remotely technical about the transient drop in snta price this morning. It was obviously a reaction to the INFI trial. I explained why I thought it was unwarranted.
Ivan, that isn't current as SNTA added a third arm, Ganetespib + Paclitaxel. I will repeat, there is no way the final trial data from 70 patients will be oriented this December.
Petco, if you really did read my posts and compared them to the voluminous repetitive, rambling and often contradictory posts of JFK, and somehow find me lacking and him valuable, there are two obvious conclusions. You are either JFK using an alias, or you come from the same boiler room operation. The childish and unwarranted name calling makes the former more likely. In any event, You, like him are now on ignore.
SNTA definitely needs more cash. I would be surprised if they don't issue some shares before Galaxy-1 final results are released. They need to do this as insurance. Obviously they won't if they generate a partnership deal before the final Galaxy-1 results are in, but they do need to raise cash one way or another. If people can't see this they shouldn't be invested in SNTA or any other biotech for that matter.